WuXi XDC Cayman Inc (2268) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of WuXi XDC Cayman Inc HK$43.22, price HK$82.00, upside -47.3%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch WuXi XDC Cayman Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
34‑month range HK$12.98 – HK$85.10 · fair‑value band HK$28.70 – HK$53.74 · the HK$82.00 price screens above the HK$43.22 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow WuXi XDC Cayman in your weekly email
Every Wednesday you see whether WuXi XDC Cayman is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally.
Show more
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. Additionally, the company engages in the research and development, manufacturing, and marketing of anti-tumor drugs. WuXi XDC Cayman Inc. has a strategic collaboration with Earendil Labs; and Akari Therapeutics. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.
Stock analysis
WuXi XDC Cayman Inc (2268) currently trades at HK$82.00, while our model-based Fair Value estimate is HK$43.22, 47.3% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of HK$59.10 per share, and 0 of the 24 models we run sit above the HK$82.00 price.
Bear case: the Asset-Based group reads lowest at HK$6.66, and 24 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: HK$28.70 (bear) to HK$53.74 (bull), the price of HK$82.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
WuXi XDC Cayman Inc reported revenue of 5.9B CNY in FY2025 versus 311M CNY in FY2021, a compound +109.1%/yr. Reported net income was 1.5B CNY in FY2025, compounding +127.9%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.
Key figures
Market cap HK$109B (≈ $13.9B) · P/E ratio 45.6 · P/S ratio 11.4 · EPS (TTM) HK$0.5700 · Net margin 24.9% · Return on equity 17.1% · Return on assets (EBIT) 7.8% · Operating margin 26.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 4% below its 52-week high and 79% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −47%, 2268 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (HK$6.66 to HK$65.09). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear HK$28.70Fair Value HK$43.22Bull HK$53.74
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (HK$0.4279 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.77/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+46.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+81.7%
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.8%
’12
’13
’14
’15
’16
’17
’18
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−6.6% (2020) → 27.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: rate outside our plausibility band
not computed
Growth Forecast
A lot of optimism in the price
The price assumes less growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+49.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+29.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +47.1% a year for the price and +27.6% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (79 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 138 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score52 · Below median
Fair Value upside−47.3% · Below median
Profitability
Return on equity (TTM)17.1% · Top 25%
Return on assets8.6% · Top 25%
Net margin (TTM)24.9% · Top 25%
Operating margin (TTM)26.3% · Top 25%
Growth and dividend
Revenue growth35.9% · Top 25%
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/E (TTM)45.6× · Pricier than median
P/B8.65× · Priciest 25%
P/S (TTM)15.62× · Priciest 25%
P/FCF146.3× · Priciest 25%
EV/EBITDA51.7× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 21
PAST (return on equity)68· sector 8
HEALTH (low debt)100· sector 94
DIVIDEND (yield)0· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is WuXi XDC Cayman Inc (2268) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of HK$43.22 versus a price of HK$82.00, about −47% upside (overvalued).
What is the fair value of 2268?
Our model-based fair value for WuXi XDC Cayman Inc is HK$43.22 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$82.00.
What is the quality score of 2268?
WuXi XDC Cayman Inc has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for WuXi XDC Cayman Inc (2268)?
Our model-based price target is the fair value of HK$43.22 (as of Sep 27, 2026) from 24 valuation models. Cautious scenario HK$28.70, optimistic scenario HK$53.74. It is a calculation from audited fundamentals, not an analyst target.
What is the WuXi XDC Cayman Inc stock forecast for 2026?
Our models put fair value at HK$43.22, about −47% upside versus a price of HK$82.00 (overvalued). Cautious scenario HK$28.70, optimistic scenario HK$53.74. The calculation is refreshed regularly with new filings.
What is the revenue of WuXi XDC Cayman Inc (2268)?
WuXi XDC Cayman Inc reported trailing-twelve-month revenue of about 5.9B CNY (latest available figure, as of Sep 27, 2026).
What growth is priced into WuXi XDC Cayman Inc (2268)?
For today's price to be fair in a discounted-cash-flow model, WuXi XDC Cayman Inc would have to grow free cash flow by +49.6 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +128.1 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of 2268 use?
Our models discount WuXi XDC Cayman Inc at 10.3 %: a base by market capitalisation (mid), country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For WuXi XDC Cayman Inc that is +49.6 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has WuXi XDC Cayman Inc (2268) delivered so far?
Over the past 5 years revenue at WuXi XDC Cayman Inc grew +128.1 % a year. The price currently implies +49.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of WuXi XDC Cayman Inc (2268) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into WuXi XDC Cayman Inc (+49.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of WuXi XDC Cayman Inc (2268)?
The free-cash-flow yield on the price is 0.68 %: that much free cash flow WuXi XDC Cayman Inc produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of WuXi XDC Cayman Inc (2268)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For WuXi XDC Cayman Inc it is HK$43.22 per share (as of Sep 27, 2026), against a price of HK$82.00. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is WuXi XDC Cayman Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 2268 trades above its calculated fair value: price HK$82.00, fair value HK$43.22, a gap of about −47% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2268?
No. The price is what the market pays today (HK$82.00); the fair value is what the company's own numbers justify (HK$43.22). For WuXi XDC Cayman Inc the two are HK$38.78 per share apart. That gap is exactly why we show both numbers side by side.
How much is WuXi XDC Cayman Inc worth?
The market values WuXi XDC Cayman Inc at about HK$109B (market capitalisation, as of Sep 27, 2026). Per share that is HK$82.00; our models calculate a fair value of HK$43.22 per share.
What do the bullish and bearish scenarios say about 2268?
Our models span a range for WuXi XDC Cayman Inc: cautious scenario HK$28.70, base HK$43.22, optimistic HK$53.74 per share (as of Sep 27, 2026, price HK$82.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 2268?
WuXi XDC Cayman Inc trades at a price-to-earnings ratio of 45.6 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$43.22 is built from several models across several years. Other multiples: P/B 8.7, P/S 15.6, EV/EBITDA 51.7.
How solid is the balance sheet of WuXi XDC Cayman Inc (2268)?
Balance-sheet figures for WuXi XDC Cayman Inc (as of Sep 27, 2026): return on equity 17.1%, debt of 0.00 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is 2268 from its 52-week high?
WuXi XDC Cayman Inc trades at HK$82.00, about 4% below its 52-week high of HK$85.10 and 79% above the low of HK$45.84 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$43.22 is for.
Which stocks are comparable to WuXi XDC Cayman Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is WuXi XDC Cayman Inc stock attractive at the current price?
The data as of Sep 27, 2026: price HK$82.00, calculated fair value HK$43.22 (−47%), Quality Score 52/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2268 calculated?
We run WuXi XDC Cayman Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$43.22, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. WuXi XDC Cayman Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of WuXi XDC Cayman Inc (2268)?
The closing price on Sep 30, 2026 was HK$82.00. Our model-based fair value is HK$43.22, about −47% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with WuXi XDC Cayman Inc right now?
The price sits above even our optimistic bull case (HK$53.74). The favourable scenario is already priced in. Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (HK$28.70 to HK$53.74) leaves room in how you read the outcome.
Key figures of WuXi XDC Cayman Inc
How large is the market capitalisation of WuXi XDC Cayman Inc (2268)?
The market capitalisation of WuXi XDC Cayman Inc is HK$109B (≈ $13.9B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of WuXi XDC Cayman Inc (2268)?
The price-to-sales ratio of WuXi XDC Cayman Inc is 11.4 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of WuXi XDC Cayman Inc (2268)?
Earnings per share at WuXi XDC Cayman Inc are HK$0.5700 (price ÷ EPS = P/E 45.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of WuXi XDC Cayman Inc (2268)?
The net margin of WuXi XDC Cayman Inc is 24.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of WuXi XDC Cayman Inc (2268)?
The return on equity (ROE) of WuXi XDC Cayman Inc is 17.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of WuXi XDC Cayman Inc (2268)?
On an EBIT basis the return on assets of WuXi XDC Cayman Inc is 7.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of WuXi XDC Cayman Inc (2268)?
The operating margin of WuXi XDC Cayman Inc is 26.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at WuXi XDC Cayman Inc (2268)?
Revenue at WuXi XDC Cayman Inc is growing +35.9% versus a year earlier (3y avg +81.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at WuXi XDC Cayman Inc (2268)?
Earnings per share at WuXi XDC Cayman Inc are growing +22.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does WuXi XDC Cayman Inc (2268) hold?
WuXi XDC Cayman Inc holds more cash than debt, 632M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch WuXi XDC Cayman Inc in the live analysis
One click puts WuXi XDC Cayman Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
